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Significant advances in our knowledge about interventions to
prevent cardiovascular disease (CVD) have occurred since
publication of the first female-specific recommendations for
preventive cardiology in 1999 (1). Despite research-based
gains in the treatment of CVD, it remains the leading killer of
women in the United States and in most developed areas of
the world (2,3). In the United States alone, more than one half
million women die of CVD each year, exceeding the number
of deaths in men and the next 7 causes of death in women
combined. This translates into approximately 1 death every
minute (2). Coronary heart disease (CHD) accounts for the
majority of CVD deaths in women, disproportionately afflicts
racial and ethnic minorities, and is a prime target for
prevention (1,2). Because CHD is often fatal, and because
nearly two thirds of women who die suddenly have no
previously recognized symptoms, it is essential to prevent
CHD (2). Other forms of atherosclerotic/thrombotic CVD,
such as cerebrovascular disease and peripheral arterial dis-
ease, are critically important in women. Strategies known to
reduce the burden of CHD may have substantial benefits for
the prevention of noncoronary atherosclerosis, although they
have been studied less extensively in some of these settings.
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In the wake of the reports of the Women’s Health Initiative
and the Heart and Estrogen/Progestin Replacement Study
(HERS), which unexpectedly showed that combination hor-
mone therapy was associated with adverse CVD effects, there
is a heightened need to critically review and document
strategies to prevent CVD in women (4–7). These studies
underscore the importance of evidence-based practice for
chronic disease prevention. Optimal translation and imple-
mentation of science to improve preventive care should
include a rigorous process of evaluation and clear communi-
cation about the quantity and quality of evidence used to
support clinical recommendations. Recently, there has been
an increase in the number and proportion of women that have
participated in clinical trials, although many early CVD
prevention trials did not fully include women and other
important subpopulations (8). Therefore, it is important to
consider the full range of available evidence, including data
on men as appropriate, to develop recommendations for
diverse populations of women. Furthermore, because many
patients seen in clinical practice may have characteristics that
are not similar to those of clinical trial participants, it is
necessary to draw inferences about the likelihood that data
will generalize from research to clinical settings.
The objective of this collaborative effort was to develop
the first set of evidence-based guidelines for the prevention of
CVD in adult women with a broad range of cardiovascular
risk. The technology for identifying CVD in its earliest stages
has improved over the past decade, and this has led to a
blurring of the distinction between primary and secondary
prevention. The concept of CVD as a categorical, “have-or-
have-not” condition has been replaced with a growing appre-
ciation for the existence of a continuum of CVD risk. Table
1 illustrates a spectrum of CVD, showing risk groups defined
by their absolute probability of having a coronary event in 10
years according to the Framingham Risk Score for women (9)
Clinical diagnoses and scenarios that broadly group women
into categories of high, intermediate, and lower risk also are
provided. This scheme allows healthcare providers to match
the intensity of risk intervention to the baseline level of CVD
risk. A scoring sheet for use in clinical practice to calculate
absolute 10-year CHD risk in women is provided in Appen-
dix I. The recommendations herein are designed to assist
healthcare providers in optimizing CVD preventive care for
all women age 20 years and older. Implementation of these
guidelines may differ among countries and regions for cul-
tural, medical, and economic reasons. In addition, application
of these guidelines should also take into consideration indi-
vidual factors such as frailty and life expectancy.
Methods
Selection of Expert Panel Members
The leadership of each of the 13 American Heart Association
(AHA) Scientific Councils was asked to nominate a recog-
nized expert in CVD prevention who had particular knowl-
edge about women. The president of the AHA appointed
at-large members to fill gaps in specific areas of expertise.
The AHA Manuscript Oversight Committee approved the
chair of the Expert Panel. On the basis of recommendations of
the AHA Expert Panel, major professional or government
organizations with a mission consistent with CVD prevention
were solicited to serve as cosponsors and were asked to
nominate 1 representative with full voting rights to serve on
the Expert Panel. Panelists also suggested diverse profes-
sional and community organizations to endorse the final
document after its approval by the AHA Science Advisory
Coordinating Committee and cosponsoring organizations.
TABLE 1. Spectrum of CVD Risk in Women
Risk Group
Framingham Global Risk
(10-y Absolute CHD Risk) Clinical Examples
High risk 20% • Established CHD
• Cerebrovascular disease*
• Peripheral arterial disease
• Abdominal aortic aneurysm
• Diabetes mellitus
• Chronic kidney disease†
Intermediate risk 10% to 20% • Subclinical CVD‡ (eg, coronary calcification)
• Metabolic syndrome
• Multiple risk factors§
• Markedly elevated levels of a single risk factor
• First-degree relative(s) with early-onset (age: 55 y in men and 65 y in women)
atherosclerotic CVD
Lower risk 10% • May include women with multiple risk factors, metabolic syndrome, or 1 or no risk factors
Optimal risk 10% • Optimal levels of risk factors and heart-healthy lifestyle
CHD indicates coronary heart disease; CVD, cardiovascular disease.
*Cerebrovascular disease may not confer high risk for CHD if the affected vasculature is above the carotids. Carotid artery disease (symptomatic or asymptomatic
with 50% stenosis) confers high risk.
†As chronic kidney disease deteriorates and progresses to end-stage kidney disease, the risk of CVD increases substantially.
‡Some patients with subclinical CVD will have 20% 10-year CHD risk and should be elevated to the high-risk category.
§Patients with multiple risk factors can fall into any of the 3 categories by Framingham scoring.
Most women with a single, severe risk factor will have a 10-year risk 10%.
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Selection of Topics and
Candidate Recommendations
The Expert Panel reviewed previously published AHA rec-
ommendations for the primary and secondary prevention of
CVD and discussed and debated topics that were timely, with
the goal of developing a set of candidate recommendations
for searching and rating (1,10–11). A list of preselected
recommendations was circulated to the panel, and experts
were asked to independently rate the priority of the recom-
mendation and suggest modifications to the wording. Recom-
mendations were then selected for the systematic literature
search.
Systematic Search and Summary of Data
Inclusion and exclusion criteria for studies to be evaluated as
part of the evidence-rating process were established according to
the Expert Panel recommendation to focus on major CVD
clinical end points (death, myocardial infarction, stroke, revas-
cularization procedure, congestive heart failure, or a composite
CVD end point) in high-quality studies. The importance of other
outcomes, such as quality of life and resource utilization, was
recognized, but these were not feasible to include in this version.
The purpose of the clinical recommendations is to provide
guidance with regard to risk-reducing interventions; therefore,
the panel supported the inclusion of studies that were interven-
tional rather than etiologic in nature. For example, studies of the
impact of weight loss on major clinical CVD outcomes were
included but not studies that simply related obesity to CVD.
Inclusion criteria were randomized clinical trials or large pro-
spective cohort studies (1000 subjects) with CVD risk–reduc-
ing interventions evaluated. Also, meta-analyses that used a
quantitative systematic review process were included. All stud-
ies had to have at least 10 cases of major clinical CVD end
points reported. Studies with surrogate end points were excluded
unless they met the minimum number of outcome events.
Studies meeting the above criteria were included whether or not
there were female participants.
The systematic search was conducted by the Duke Center for
Clinical Health Policy Research, Durham, NC. Search terms
were constructed for each clinical recommendation, with an
“explode” term to include related articles. Three databases were
searched electronically on OVID, including Medline (1966
through July 3, 2003), the Cumulative Index to Nursing & Allied
Health (CINAHL) (1982 through July 3, 2003), and PsycInfo
(1872 through July 3, 2003). More than 99% of the studies were
located in Medline. Nearly 7000 titles and abstracts identified
through the systematic search were reviewed to exclude those
that did not meet obvious eligibility criteria or were not available
in English. More than 1200 articles were obtained for full-text
screening and reviewed for inclusion/exclusion criteria. A stan-
dardized abstraction form was completed to document the study
design, end points, and decision to include or exclude. Table 2
lists the number of articles included/excluded for each category
of recommendation.
TABLE 2. Summary of Articles Identified From Systematic Literature Review by Topic
Topic
Abstracts
Identified
Articles Included
for Full-Text
Screening
Meta-Analyses
Identified
Articles Included
for Evidence
Tables
Hyperlipidemia 339 119 5 40
Physical activity 950* 95 6 52
Tobacco use 1341 127 6 16
Antiplatelet therapy 753 155 12 31
Blood pressure management 273 112 16 31
-Blocker therapy 845 136 12 30
Cardiac rehabilitation 950* 69 4 19
ACE/ARB therapy 371 48 7 21
Weight management 158 25 1 6
Diabetes 229 56 2 8
Hormone replacement therapy 373 93 5 41
Diet modification 425 89 4 68
Warfarin in atrial fibrillation 242 49 6 11
Aspirin for primary prevention 25 15 3 10
Depression therapy 45 5 0 2
Antioxidant supplementation 220 43 0 16
Omega-3 fatty acid supplementation 169 45 2 8
Folic acid supplementation 69 10 1 3
Total† 6819 1279 92 399
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker.
*Physical activity and cardiac rehabilitation were combined during the initial literature search. This number reflects
the total number of abstracts identified as physical activity OR cardiac rehabilitation.
†Total numbers reflect unique articles. Actual sum of the individual recommendation numbers are higher than total
due to the inclusion of some articles under more than one recommendation. The exception is the total articles included
for evidence tables, which reflects the number of tables that appear in the report.
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Included articles were abstracted for more detailed informa-
tion on a standardized form that included study type, number of
participants (% female) at baseline, population characteristics
(primary prevention, secondary prevention, or mixed), mean age
(age range), percentage diabetic, percentage white, interven-
tion(s) (for drug trials, information was listed about dose,
schedule, and duration), primary outcomes including numbers of
events, subgroup analysis of clinical end points in women (if
analysis available), and comments about important methodolog-
ical or quality issues.
Expert Panel members reviewed the summary evidence tables
for completeness. Tables were updated with publications that were
inadvertently omitted or included during the systematic search to
comprise the final evidence tables. In addition, results of trials or
meta-analyses published subsequent to the systematic search that
met inclusion criteria were made available to the Expert Panel. A
complete listing of references reviewed by the Expert Panel and
used to compile the evidence summary tables is listed in Appendix
II. The evidence summary tables are located in an online-only Data
Supplement at http://www.circulationaha.org.
Evidence Rating System
Two primary reviewers from the Expert Panel were assigned to
each candidate recommendation to propose an initial evidence
rating and suggest modifications to wording on the basis of the
results of the systematic evidence search. A series of conference
calls was held to discuss the rating and revised wording of
recommendations. Each expert received a final copy of the
evidence tables and voted independently on the strength of the
recommendation (Class I, IIa, IIb, or III) and level of evidence
(A, B, or C) as outlined in Table 3. Class I interventions should
be administered unless contraindicated. Class III interventions
should not be administered for CVD prevention. The rationale
for the rating system is based on methods used in AHA/
American College of Cardiology clinical practice guidelines as
described (12). The experts also evaluated the likelihood that
data from men would generalize to women with regard to each
specific risk-reducing intervention (1, very likely; 2, somewhat
likely; 3, unlikely; and 0, unable to project). Criteria to determine
generalizability were based on factors such as differences in the
epidemiology and pathophysiology of CVD between men and
women (eg, the ratio of hemorrhagic stroke to coronary events
may alter the risk-to-benefit ratio of aspirin in primary preven-
tion for women versus men). The final rating of evidence was
determined by a majority vote.
Clinical Recommendations
Evidence-based recommendations for the prevention of CVD in
women are listed in Table 4. Each recommendation is accom-
panied by the strength of recommendation, level of evidence to
support it, and the generalizability index. The strength of the
recommendation is based on not only the level of evidence to
support a clinical recommendation, but also on factors such as
feasibility of conducting randomized controlled trials in women.
Recommendations are grouped in the following categories:
lifestyle interventions; major risk factor interventions; atrial
fibrillation/stroke prevention; preventive drug interventions; and
a Class III category, where routine intervention for CVD
prevention is not recommended.
Several lifestyle interventions were rated as Class I recom-
mendations, although the supporting evidence was in many
cases classified as level B. These decisions reflect the
availability of observational studies as evidence to support
the recommendation, as well as ethical issues that preclude
conducting randomized controlled trials of certain lifestyle
interventions. For example, the Expert Panel regarded smok-
ing cessation as a top priority in clinical practice and
suggested that the absence of trial data should not preclude a
strong emphasis on clinician interventions to help women
stop smoking. More detailed information on how to treat
tobacco dependence is available at http://www.surgeongener-
al.gov/tobacco/treating_tobacco_use.pdf (Table 5).
Lifestyle interventions received Class I recommendations
from the panel not only because of their potential to reduce
clinical CVD, but also because heart-healthy lifestyles may
prevent the development of major risk factors for CVD (13).
Prevention of the development of risk factors through a positive
lifestyle approach may minimize the need for more intensive
intervention in the future.
Although evidence to support a clinical benefit for CVD event
reduction was limited with some interventions (eg, treatment of
depression), there may be other important benefits associated with
these therapies that are reflected in the strength of the recommen-
dation, such as improved quality of life. Behavioral interventions
may have benefits that are not captured by our stringent outcome
criteria for clinical CVD events. Weight management via lifestyle
and behavioral approaches was rated as a Class I recommendation,
level B. The panel suggested there was insufficient evidence to rate
more aggressive medical and surgical approaches that generally are
limited to a small subset of women.
TABLE 3. Classification and Levels of Evidence
Strength of Recommendation
Classification
Class I Intervention is useful and effective
Class IIa Weight of evidence/opinion is in favor of
usefulness/efficacy
Class IIb Usefulness/efficacy is less well established by
evidence/opinion
Class III Intervention is not useful/effective and may be
harmful
Level of Evidence
A Sufficient evidence from multiple randomized
trials
B Limited evidence from single randomized trial or
other nonrandomized studies
C Based on expert opinion, case studies, or
standard of care
Generalizability index
1 Very likely that results generalize to women
2 Somewhat likely that results generalize to
women
3 Unlikely that results generalize to women
0 Unable to project whether results generalize to
women
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TABLE 4. Clinical Recommendations
Lifestyle interventions
Cigarette smoking
Consistently encourage women not to smoke and to avoid environmental tobacco. (Class I, Level B)GI1
Physical activity
Consistently encourage women to accumulate a minimum of 30 minutes of moderate-intensity physical activity (eg, brisk
walking) on most, and preferably all, days of the week. (Class I, Level B)GI1
Cardiac rehabilitation
Women with a recent acute coronary syndrome or coronary intervention, new-onset or chronic angina should participate in a
comprehensive risk-reduction regimen, such as cardiac rehabilitation or a physician-guided home- or community-based
program. (Class I, Level B)GI2
Heart-healthy diet
Consistently encourage an overall healthy eating pattern that includes intake of a variety of fruits, vegetables, grains, low-fat
or nonfat dairy products, fish, legumes, and sources of protein low in saturated fat (eg, poultry, lean meats, plant sources).
Limit saturated fat intake to 10% of calories, limit cholesterol intake to 300 mg/d, and limit intake of trans fatty acids.
(Class I, Level B)GI1
Weight maintenance/reduction
Consistently encourage weight maintenance/reduction through an appropriate balance of physical activity, caloric intake, and
formal behavioral programs when indicated to maintain/achieve a BMI between 18.5 and 24.9 kg/m2 and a waist
circumference 35 in. (Class I, Level B)GI1
Psychosocial factors
Women with CVD should be evaluated for depression and refer/treat when indicated. (Class IIa, Level B)GI2
Omega 3 fatty acids
As an adjunct to diet, omega 3 fatty-acid supplementation may be considered in high-risk* women. (Class IIb, Level B)GI2
Folic acid
As an adjunct to diet, folic acid supplementation may be considered in high-risk* women (except after revascularization
procedure) if a higher-than-normal level of homocysteine has been detected. (Class IIb, Level B)GI2
Major risk factor interventions
Blood pressure—lifestyle
Encourage an optimal blood pressure of 120/80 mm Hg through lifestyle approaches. (Class I, Level B)GI1
Blood pressure— drugs
Pharmacotherapy is indicated when blood pressure is 140/90 mm Hg or an even lower blood pressure in the setting of
blood pressure–related target-organ damage or diabetes. Thiazide diuretics should be part of the drug regimen for most
patients unless contraindicated. (Class I, Level A)GI1
Lipid, lipoproteins
Optimal levels of lipids and lipoproteins in women are LDL-C 100 mg/dL, HDL-C 50 mg/dL, triglycerides 150 mg/dL,
and non–HDL-C (total cholesterol minus HDL cholesterol) 130 mg/dL and should be encouraged through lifestyle
approaches. (Class I, Level B)GI1
Lipids—diet therapy
In high-risk women or when LDL-C is elevated, saturated fat intake should be reduced to 7% of calories, cholesterol to
200 mg/d, and trans fatty acid intake should be reduced. (Class I, Level B)GI1
Lipids—pharmacotherapy—high risk*
Initiate LDL-C–lowering therapy (preferably a statin) simultaneously with lifestyle therapy in high-risk women with LDL-C
100 mg/dL (Class I, Level A)GI1, and initiate statin therapy in high-risk women with an LDL-C 100 mg/dL unless
contraindicated (Class I, Level B)GI1.
Initiate niacin§ or fibrate therapy when HDL-C is low, or non–HDL-C elevated in high-risk women. (Class I, Level B)GI1
GI indicates generalizability index; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; ACE,
angiotensin-converting enzyme; and ARB, angiotensin receptor blocker.
*High risk is defined as CHD or risk equivalent, or 10-year absolute CHD risk 20%.
†Intermediate risk is defined as 10-year absolute CHD risk 10% to 20%.
‡Lower risk is defined as 10-year absolute CHD risk 10%.
§Dietary supplement niacin must not be used as a substitute for prescription niacin, and over-the-counter niacin should only be
used if approved and monitored by a physician.
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TABLE 4. Continued
Lipids—pharmacotherapy—intermediate risk†
Initiate LDL-C–lowering therapy (preferably a statin) if LDL-C level is 130 mg/dL on lifestyle therapy (Class I, Level A)GI1, or
niacin§ or fibrate therapy when HDL-C is low or non–HDL-C elevated after LDL-C goal is reached. (Class I, Level B)GI1
Lipids—pharmacotherapy—lower risk‡
Consider LDL-C–lowering therapy in low-risk women with 0 or 1 risk factor when LDL-C level is 190 mg/dL or if multiple
risk factors are present when LDL-C is 160 mg/dL (Class IIa, Level B) or niacin§ or fibrate therapy when HDL-C is low or
non–HDL-C elevated after LDL-C goal is reached. (Class IIa, Level B)GI1
Diabetes
Lifestyle and pharmacotherapy should be used to achieve near normal HbA1C (7%) in women with diabetes. (Class I, Level
B)GI1
Preventive drug interventions
Aspirin—high risk*
Aspirin therapy (75 to 162 mg), or clopidogrel if patient is intolerant to aspirin, should be used in high-risk women unless
contraindicated. (Class I, Level A)GI1
Aspirin—intermediate risk†
Consider aspirin therapy (75 to 162 mg) in intermediate-risk women as long as blood pressure is controlled and benefit is
likely to outweigh risk of gastrointestinal side effects. (Class IIa, Level B)GI2
-Blockers
-Blockers should be used indefinitely in all women who have had a myocardial infarction or who have chronic ischemic
syndromes unless contraindicated. (Class I, Level A)GI1
ACE inhibitors
ACE inhibitors should be used (unless contraindicated) in high-risk* women. (Class I, Level A)GI1
ARBs
ARBs should be used in high-risk* women with clinical evidence of heart failure or an ejection fraction 40% who are
intolerant to ACE inhibitors. (Class I, Level B)GI1
Atrial fibrillation/stroke prevention
Warfarin—atrial fibrillation
Among women with chronic or paroxysmal atrial fibrillation, warfarin should be used to maintain the INR at 2.0 to 3.0 unless
they are considered to be at low risk for stroke (1%/y) or high risk of bleeding. (Class I, Level A)GI1
Aspirin—atrial fibrillation
Aspirin (325 mg) should be used in women with chronic or paroxysmal atrial fibrillation with a contraindication to warfarin or
at low risk for stroke (1%/y). (Class I, Level A)GI1
Class III interventions
Hormone therapy
Combined estrogen plus progestin hormone therapy should not be initiated to prevent CVD in postmenopausal women. (Class
III, Level A)
Combined estrogen plus progestin hormone therapy should not be continued to prevent CVD in postmenopausal women.
(Class III, Level C)
Other forms of menopausal hormone therapy (eg, unopposed estrogen) should not be initiated or continued to prevent CVD in
postmenopausal women pending the results of ongoing trials. (Class III, Level C)
Antioxidant supplements
Antioxidant vitamin supplements should not be used to prevent CVD pending the results of ongoing trials. (Class III, Level
A)GI1
Aspirin—lower risk‡
Routine use of aspirin in lower-risk women is not recommended pending the results of ongoing trials. (Class III, Level B)GI2
GI indicates generalizability index; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; ACE,
angiotensin-converting enzyme; and ARB, angiotensin receptor blocker.
*High risk is defined as CHD or risk equivalent, or 10-year absolute CHD risk 20%.
†Intermediate risk is defined as 10-year absolute CHD risk 10% to 20%.
‡Lower risk is defined as 10-year absolute CHD risk 10%.
§Dietary supplement niacin must not be used as a substitute for prescription niacin, and over-the-counter niacin should only be
used if approved and monitored by a physician.
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Our dietary recommendations emphasize intake of a variety
of heart-healthy foods. The panel concluded that intake of fish
has been associated with a reduced risk of CVD. The benefits of
fish seem to result, at least in part, from omega-3 fatty acids.
Nonetheless, women of childbearing age, especially pregnant
women, should avoid shark, swordfish, king mackerel, and
tilefish because the relatively high content of mercury in these
fish may impair fetal neurological development. Still, these
women can eat other kinds of fish, such as catfish, flounder, and
salmon, which have less mercury. For a more complete listing of
mercury levels in different types of fish, see the US Food and
Drug Administration web site at http://www.cfsan.fda.gov/~frf/
sea-mehg.html (Table 5). Women who do not eat fish might
consider nonmarine sources of omega-3 fatty acids, such as
flaxseed oil, walnut oil, canola oil, soybean oil, or walnuts.
However, there is less evidence supporting a cardiovascular
benefit from these sources of omega-3 fatty acids (14).
Other expert panels and organizations (including the National
Cholesterol Education Program Adult Treatment Panel III
[NCEP ATP III]; the Seventh Report of the Joint National
Committee on Prevention, Detection, Evaluation, and Treatment
of High Blood Pressure [JNC 7], and the American Diabetes
Association) have addressed control of major risk factors exten-
sively and can be referred to for more specific information about
management approaches (Table 5) (9,15,16). For example, our
recommendation to encourage an optimal blood pressure
through lifestyle approaches should be implemented using more
detailed information from the JNC 7 report about weight
management, adopting a DASH (Dietary Approaches to Stop
Hypertension) eating plan, dietary sodium reduction, physical
activity, and moderation of alcohol consumption (15). Similarly,
NCEP ATP III provides algorithms for cholesterol management
and is updated as new evidence becomes available (9). Accord-
ing to NCEP/ATP III, LDL cholesterol is the primary target of
lipid-lowering therapy, and intensity of therapy should be
matched to the absolute risk of the patient. Glycemic control
received a Class I recommendation from the Expert Panel.
Treatment of hyperglycemia has been shown to reduce or delay
complications of diabetes such as retinopathy, nephropathy, and
neuropathy, which underscores the importance of glycemic
control in diabetic patients (16). Moreover, both lifestyle inter-
vention and (to a lesser degree) metformin therapy have been
shown to reduce the incidence of diabetes (17).
Although there was good consensus on the use of aspirin
(75 to 162 mg) in high-risk women, recommendations for
aspirin therapy in intermediate- and lower-risk women were
more challenging. The difficulty in developing these recom-
mendations was due to the lack of data from primary
prevention trials that included women and the possibility that
data on men may not necessarily be extrapolated to women.
TABLE 5. Internet Resources With Supporting Materials for Selected Recommendations
Clinical Recommendation Recommended Web Site Comments
Cigarette smoking http://www.surgeongeneral.gov/tobacco/
treating_tobacco_use.pdf
Treating Tobacco Use and Dependence
Diet http://www.cfsan.fda.gov/frf/sea-mehg.html Mercury Levels in Seafood Species
Weight management http://www.nhlbi.nih.gov/guidelines/obesity/ob_home.htm Clinical Guidelines on the Identification, Evaluation, and
Treatment of Overweight and Obesity in Adults
Lipids http://circ.ahajournals.org/cgi/reprint/106/25/3143.pdf Third Report of the National Cholesterol Education Program
Adult Treatment Panel III (NCEP ATP III)
Blood pressure http://hyper.ahajournals.org/cgi/content/full/42/6/1206 Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure (JNC 7)
http://www.nhlbi.nih.gov/health/public/heart/hbp/dash/
index.htm
Dietary Approaches to Stop Hypertension (DASH) Eating
Plan
Diabetes http://www.diabetes.org/home.jsp American Diabetes Association
http://circ.ahajournals.org/cgi/content/full/105/18/2231 AHA Conference Proceedings: Prevention Conference VI:
Diabetes and Cardiovascular Disease
Atrial fibrillation/stroke prevention http://www.nhlbi.nih.gov/about/framingham/stroke.htm Framingham Stroke Risk Scoring System
http://www.americanheart.org/downloadable/heart/
222_ja20017993p_1.pdf
ACC/AHA/ESC Guidelines for the Management of Patients
With Atrial Fibrillation
Absolute CHD risk calculation http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm Framingham CHD Risk Scoring System
All sites were accessed on and available as of December 16, 2003.
TABLE 6. CVD Prevention Strategies for Clinical Practice
1. Assess and stratify women into high, intermediate, lower, or optimal
risk categories.
2. Lifestyle approaches (smoking cessation, regular exercise, weight
management, and heart-healthy diet) to prevent CVD are Class I
recommendations for all women and a top priority in clinical practice.
3. Other CVD risk–reducing interventions should be prioritized on the
basis of strength of recommendation (Class I  Class IIa  Class IIb)
and within each class of recommendation on the basis of the level of
evidence, with the exception of lifestyle, which is a top priority for all
women (ABC).
4. Highest priority for risk intervention in clinical practice is based on risk
stratification: (high risk  intermediate risk  lower risk  optimal
risk).
5. Avoid interventions designated as Class III.
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Uncontrolled hypertension is not uncommon in women, and
aspirin therapy may increase the risk of hemorrhagic stroke in
this setting. Moreover, the risk of gastrointestinal bleeding
and other side effects may outweigh the potential benefits of
aspirin in women at lower risk for CVD. The panel suggested
a conservative approach, pending the results of ongoing
clinical trials. It was also noted that nonsteroidal antiinflam-
matory medications should not be substituted for aspirin for
CVD prevention. For stroke prevention among women with
atrial fibrillation, a dose of 325 mg of aspirin is needed if
there is a contraindication to warfarin therapy or if the risk of
a stroke is considered low (1% annual event rate per year).
Tools to determine stroke risk are available at http://www.nhlbi.
nih.gov/about/framingham/stroke.htm (Table 5).
The Class III recommendations on hormone therapy and
antioxidant supplementation were based on recent clinical
trials showing no benefit for CVD prevention and possible
adverse effects of these interventions. The panel acknowl-
edged that major trials have been limited to specific types and
dosages of these agents, and those results may not generalize
to compounds not tested in clinical studies. In particular,
ongoing trials will give more information about unopposed
estrogen therapy and clinical outcomes. However, given the
unproven benefit and possible harm associated with post-
menopausal hormone therapies, it was suggested that a
conservative approach be taken in clinical practice unless
further research is available to support use for CVD preven-
tion. The use of hormone therapy for menopausal symptoms
has been addressed by other professional societies (18,19).
Although hormone therapy is not recommended for CVD
prevention, women and their healthcare providers should
weigh the potential risks of therapy against the potential
benefits for menopausal symptom control.
Limitations
The process of developing clinical guidelines has several limi-
tations, even when a systematic approach is undertaken. Most
importantly, data used to establish recommendations might be
generated from populations that do not reflect the characteristics
of the patient being treated, and individual responses can vary
significantly. The clinical cardiovascular end points chosen for
inclusion in the systematic evaluation do not necessarily reflect
the net clinical impact and do not include many end points that
are clinically important but often not reported (eg, symptoms,
quality of life, functional status, hospitalizations, resource utili-
zation, etc). We simplified the recommendation for each level of
risk for purposes of clinical utility and acknowledge that there
might be variability in efficacy and effectiveness of various
interventions within the same risk intervention category (eg,
various doses or types of physical activity or drugs within the
same class may yield different results). The Framingham risk
score may not apply equally to all populations, but it performs
well within subgroups (20,21). We may have omitted or in-
cluded some studies because of the limitations of electronic
searching and human error; however, the likelihood that such an
inadvertent omission or inclusion would alter a recommendation
is small. Our recommendations are based on evidence available
to the panel through November 2003, and as science evolves,
recommendations may have to be revised. Finally, we do not
include a comprehensive plan for implementation of the guide-
lines in this document. The AHA is developing professional
education programs and other initiatives to facilitate the dissem-
ination and implementation of the guidelines.
Conclusions and Future Directions
Overwhelming evidence suggests that CVD can be prevented
in both women and men. Clinical recommendations are
provided to assist healthcare providers and the public in
TABLE 7. Priorities for Prevention in Practice According to
Risk Group
High-risk women (>20% risk)
Class I recommendations:
• Smoking cessation
• Physical activity/cardiac rehabilitation
• Diet therapy
• Weight maintenance/reduction
• Blood pressure control
• Lipid control/statin therapy
• Aspirin therapy
• -Blocker therapy
• ACE inhibitor therapy (ARBs if contraindicated)
• Glycemic control in diabetics
Class IIa recommendation:
• Evaluate/treat for depression
Class IIb recommendations:
• Omega 3 fatty-acid supplementation
• Folic acid supplementation
Intermediate-risk women (10% to 20% risk)
Class I recommendations:
• Smoking cessation
• Physical activity
• Heart-healthy diet
• Weight maintenance/reduction
• Blood pressure control
• Lipid control
Class IIa recommendations:
• Aspirin therapy
Lower-risk women (<10% risk)
Class I recommendations:
• Smoking cessation
• Physical activity
• Heart-healthy diet
• Weight maintenance/reduction
• Treat individual CVD risk factors as indicated
Stroke prevention among women with atrial fibrillation
Class I recommendations:
High-intermediate risk of stroke
• Warfarin therapy
Low risk of stroke (1%/y) or contraindication to warfarin
• Aspirin therapy
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor
blocker.
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efforts to avoid an initial or recurrent cardiovascular event.
Strategies to implement these guidelines and prioritize risk-
reducing therapies in clinical practice are outlined in Tables 6
and 7. Our systematic search of the literature shows that
several prevention strategies are likely to have substantially
greater benefit than risk and that some interventions are likely
to be associated with greater risk than benefit. It is important
that the public be appropriately informed about potentially
lifesaving preventive therapies and take action to lower their
risk. On the basis of our review of the scientific evidence, it
appears the risk of no action is far greater than that of
applying knowledge to prevent CVD. Approximately 75% of
the original research articles that met our inclusion criteria
included female subjects, and very few presented race/ethnic-
specific analyses. Moreover, few studies included elderly
women, especially those over 80, in whom CVD is common.
The results of this project highlight the need to include
diverse populations in research studies and to present sub-
group analyses so that guidance can be tailored, if appropri-
ate, to subpopulations. These recommendations are meant to
assist clinicians on the basis of our current state of evidence
and supersede previous AHA prevention guidelines with
regard to women (1,10,11,22). Because health care is a blend
of science and art, we emphasize that guidelines are not a
substitute for good clinical judgment.
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